Pharmacotherapeutics of SARS-CoV-2 Infections

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/714

Full metadata record

DC Field	Value	Language
dc.contributor.author	Kevadiya, B D	-
dc.contributor.author	Machhi, J	-
dc.contributor.author	Herskovitz, J et al.	-
dc.date.accessioned	2023-07-21T06:14:45Z	-
dc.date.available	2023-07-21T06:14:45Z	-
dc.date.issued	2021	-
dc.identifier.issn	1557-1904	-
dc.identifier.uri	https://link.springer.com/article/10.1007/s11481-020-09968-x	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/714	-
dc.description.abstract	The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.	en_US
dc.language.iso	en	en_US
dc.publisher	Journal of Neuroimmune Pharmacology, 16 (Springer)	en_US
dc.relation.ispartofseries	;12-37	-
dc.subject	SARS-CoV-2	en_US
dc.subject	COVID-19 therapeutics	en_US
dc.title	Pharmacotherapeutics of SARS-CoV-2 Infections	en_US
dc.type	Article	en_US
Appears in Collections:	Research Papers

Files in This Item:

File	Description	Size	Format
Book Info.docx		9.83 kB	Microsoft Word XML	View/Open